Biotech Values

[ThomasS]

MNTA: "In a general way, how will it affect "follow on" biologics that involve a highly characterized (in terms of glycosylation) small protein such as Copaxone?"
I'm sure you meant a "complex drug," as opposed to a small protein drug, as COPAXONE is not a protein in the context of traditional biologics. MNTA's FoB program with Sandoz does, however, address at least two FoB protein drugs. COPAXONE involves polypeptides; it was meant as the next stepping stone to outright protein biologics. Lovenox to Copaxone to FoB's.